* 2013 operating income up 14 pct, sales down 4.3 pct
* Pradaxa sales rise 9 pct to 1.2 bln eur in 2013
* Sees 2014 sales flat, operating income slightly up
(Adds details on Pradaxa, management quotes)
INGELHEIM, Germany, April 15 German drugmaker
Boehringer Ingelheim's operating income rose 14 percent last
year as cost cuts and sales of anti-blood-clotting drug Pradaxa
helped counter the impact of currency effects, it said on
Germany's second largest drugmaker said sales of Pradaxa,
which competes with Bayer and Johnson & Johnson's
Xarelto as well as Bristol Myers-Squibb and
Pfizer's Eliquis, jumped to 1.2 billion euros ($1.66
billion) in its third year of market approval.
The figure represented an 8.8 percent improvement in euro
terms, and more than 16 percent when adjusted for currencies.
The German group's full-year operating income rose 14
percent to 2.1 billion euros last year while sales fell 4.3
percent to 14.1 billion euros.
The company said sales were severely hit by the weak U.S.
dollar and Japanese yen. Adjusted for currency effects, sales
rose 1.4 percent.
Boehringer said sales would be flat in 2014 and operating
income would rise only slightly, adding it expects no particular
signs of growth emerging in the pharmaceutical industry in the
course of the next few years.
"The market environment for innovative medicines is not
going to get any easier in the current financial year," said
Andreas Barner, chairman of the management board.
U.S. courts are scheduled to start hearing cases against
Boehringer Ingelheim over Pradaxa in August, the drugmaker has
Claimants accuse Boehringer of not having sufficiently
warned of the risks associated with Pradaxa.
($1 = 0.7238 euros)
(Reporting by Frank Siebelt and Marilyn Gerlach; Editing by